TD Cowen analyst Dan Brennan lowered the firm’s price target on Bruker (BRKR) to $55 from $70 and keeps a Hold rating on the shares. The firm said management sees little risk even if the budget is cut and discussed a strong A&G ex-US recovering Pharma and traction with key businesses supporting a solid 25 plus healthy margins.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker: Strong Buy Rating Backed by Core Growth and Strategic Positioning in Emerging Markets
- Bruker price target lowered to $57 from $70 at Stifel
- Bruker price target lowered to $60 from $65 at Barclays
- Bruker Corporation Reports Strong 2024 Financial Results
- Cautious Hold on Bruker Amid Valuation Appeal and External Uncertainties
Questions or Comments about the article? Write to editor@tipranks.com